Open Access Review

Repurposing anti-parasite benzimidazole drugs as selective anti-cancer chemotherapeutics

by Fatemeh Movahedi a ,  Li Li a,* orcid  and  Zhi Ping Xu a,b,* orcid
a
Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, StLucia, QLD4072, Australia
b
Institute of Biomedical Health Technology and Engineering and Institute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen 518107, China
*
Author to whom correspondence should be addressed.
CI  2023 2(1):17; https://doi.org/10.58567/ci02010003
Received: 23 May 2023 / Accepted: 9 June 2023 / Published Online: 14 June 2023
View Full-Text
Download PDF

Abstract

Cancer chemotherapy is generally associated with many severe adverse effects. Many cancer studies are currently focused on repurposing conventional non-toxic anti-parasite drugs for cancer treatment. Since cancer cells and parasites have many features in common, some anti-parasite drugs such as benzimidazoles have been recently found to possess the anti-cancer activity. Benzimidazoles act against cancer by inhibiting tubulin polymerization, inducing cancer cell apoptosis, arresting cell cycle and over-generating reactive oxygen specimen. In this review, we summarize the anticancer features of these drugs in recent investigations, lead to reconsideration of benzimidazoles as a family of anti-cancer chemotherapeutics with non-toxicity or low toxicity to the normal cells and tissues. We particularly highlight the recent progresses using nanoformulations for enhanced cancer therapy and provide our prospects in the future research.

Keywords: Anti-parasite; Benzimidazoles; Anti-cancer activity; Inhibition of tubulin polymerization; Selective chemoth erapeutics;
Copyright: © 2023 by Movahedi, Li and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (Creative Commons Attribution 4.0 International License). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Show Figures

Funding

Australian Research Council (ARC) Discovery Projects (DP190103486)

Share and Cite

ACS Style
Movahedi, F.; Li, L.; Xu, Z. P. Repurposing anti-parasite benzimidazole drugs as selective anti-cancer chemotherapeutics. Cancer Insight, 2023, 2, 17. https://doi.org/10.58567/ci02010003
AMA Style
Movahedi F, Li L, Xu Z P. Repurposing anti-parasite benzimidazole drugs as selective anti-cancer chemotherapeutics. Cancer Insight; 2023, 2(1):17. https://doi.org/10.58567/ci02010003
Chicago/Turabian Style
Movahedi, Fatemeh; Li, Li; Xu, Zhi P. 2023. "Repurposing anti-parasite benzimidazole drugs as selective anti-cancer chemotherapeutics" Cancer Insight 2, no.1:17. https://doi.org/10.58567/ci02010003
APA style
Movahedi, F., Li, L., & Xu, Z. P. (2023). Repurposing anti-parasite benzimidazole drugs as selective anti-cancer chemotherapeutics. Cancer Insight, 2(1), 17. https://doi.org/10.58567/ci02010003

Article Metrics

Article Access Statistics

References

  1. Senapati S,Mahanta AK, Kumar S,Maiti P: Controlled drug delivery vehicles for cancer treatment and their performance .In: Signal Transduction and Targeted Therapy. vol. 3: Springer Nature; 2018.
  2. Lorusso D, Bria E, Costantini A, Di Maio M, Rosti G, Mancuso A: Patients ’perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life -An Italian survey . European Journal of Cancer Care 2017, 26 (2):e12618-e12618.
  3. Zhang HZ, Damu GLV, Cai GX, Zhou CH: Design, synthesis and antimicrobial evaluation of novel benzimidazole type of Fluconazole analogues and their synergistic effects with Chloromycin, Norfloxacin and Fluconazole .European Journal of Medicinal Chemistry 2013, 64 :329-344.
  4. Nixon GL, McEntee L,Johnson A, Farrington N, Whalley S,Livermore J,Natal C,Washbourn G, Bibby J,Berry Net al: Repurposing and reformulation of the antiparasitic agent flubendazole for treatment of cryptococcal meningoencephalitis, aneglected fungal disease .Antimicrobial Agents and Chemotherapy 2018, 62 (4).
  5. Bansal Y, Kaur M, Bansal G: Antimicrobial Potential of Benzimidazole Derived Molecules .Mini-Reviews in Medicinal Chemistry 2019, 19 (8):624-646.
  6. Tonelli M, Simone M, Tasso B, Novelli F,Boido V,Sparatore F,Paglietti G, Pricl S,Giliberti G, Blois Set al:Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives .Bioorganic and Medicinal Chemistry 2010, 18 (8):2937-2953.
  7. Lazer ES, Matteo MR, Possanza GJ: Benzimidazole Derivatives with Atypical Antiinflammatory Activity . Journal of Medicinal Chemistry 1987, 30 (4):726-729.
  8. Ashall F: Cancer cells and parasites: two of akind .In: Trends in Biochemical Sciences. vol. 11: Elsevier Current Trends; 1986: 518-520.
  9. Lee YT, Tan YJ, Oon CE: Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine .Acta Pharm Sin B2023, 13 (2):478-497.
  10. Kr álov áV,Hanu šováV,Sta ňkov áP,Knoppov áK, Čáň ováK, Sk álov áL: Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines .Anticancer Drugs 2013, 24 (9):911-919.
  11. Skibinski CG, Williamson T,Riggins GJ: Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma . Journal of Neuro-Oncology 2018, 140 (3):529-538.
  12. Spagnuolo PA, Hu J,Hurren R, Wang X, Gronda M, Sukhai MA, Di Meo A, Boss J,Ashali I,Zavareh RB et al:The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma .Blood 2010, 115 (23):4824-4833.
  13. Pourgholami MH, Lu Y,Morris DL: Albendazole inhibits paclitaxel-resistant 1A9PTX22 ovarian cancer cells . Cancer Research 2014, 66 (8 Supplement).
  14. Sridhar Goud N, Kumar P,Dawn Bharath R: Recent Developments of Target-Based Benzimidazole Derivatives as Potential Anticancer Agents .In: Heterocycles -Synthesis and Biological Activities [Working Title]. edn.: IntechOpen; 2020.
  15. Mukhtar E, Adhami VM, Mukhtar H: Targeting microtubules by natural agents for cancer therapy .In: Molecular Cancer Therapeutics. vol. 13: NIH Public Access; 2014: 275-284.
  16. Cheong JE, Zaffagni M, Chung I,Xu Y,Wang Y,Jernigan FE, Zetter BR, Sun L: Synthesis and anticancer activity of novel water soluble benzimidazole carbamates .European Journal of Medicinal Chemistry 2018, 144 :372-385.
  17. Carvalho KP, Gadelha APR: Effects of three benzimidazoles on growth, general morphology and ultrastructure of <i>Tritrichomonas foetus</i> .FEMS Microbiology Letters 2007, 275 (2):292-300.
  18. Horton RJ: Benzimidazoles in awormy world .Parasitology Today 1990, 6(4):106-106.
  19. Maddison JE, Page SW, Church DB: Small animal clinical pharmacology .
  20. Chai JY: Praziquantel treatment in trematode and cestode infections: An update .In: Infection and Chemotherapy. vol. 45: Korean Society of Infectious Diseases; 2013: 32-43.
  21. Keiser J,Engels D, Büscher G, Utzinger J:Triclabendazole for the treatment of fascioliasis and paragonimiasis . In: Expert Opinion on Investigational Drugs. vol. 14: Taylor &Francis; 2005: 1513-1526.
  22. Benzimidazoles -Pharmacology -Veterinary Manual .In.
  23. Mottier L, Alvarez L, Ceballos L, Lanusse C: Drug transport mechanisms in helminth parasites: Passive diffusion of benzimidazole anthelmintics .Experimental Parasitology 2006, 113 (1):49-57.
  24. Encyclopedia of Parasitology: A-M -Horst Asp öck -Google Books .In.
  25. Dawson PJ, Gutteridge WE, Gull K: A comparison of the interaction of anthelmintic benzimidazoles with tubulin isolated from mammalian tissue and the parasitic nematode Ascaridia galli .Biochemical Pharmacology 1984, 33 (7):1069-1074.
  26. Katiyar SK, Gordon VR, McLaughlin GL, Edlind TD: Antiprotozoal activities of benzimidazoles and correlations with β-tubulin sequence .Antimicrobial Agents and Chemotherapy 1994, 38 (9):2086-2090.
  27. Morgan UM, Reynoldson JA, Thompson RCA: Activities of several benzimidazoles and tubulin inhibitors against Giardia spp. in vitro .Antimicrobial Agents and Chemotherapy 1993, 37 (2):328-331.
  28. Edlind TD, Hang TL, Chakraborty PR: Activity of the anthelmintic benzimidazoles against Giardia lamblia in vitro .JInfect Dis 1990, 162 (6):1408-1411.
  29. Seiler JP: Toxicology and genetic effects of benzimidazole compounds .Mutation Research/Reviews in Genetic Toxicology 1975, 32 (2):151-167.
  30. Michaelis M, Agha B, Rothweiler F,Löschmann N, Voges Y,Mittelbronn M, Starzetz T,Harter PN, Abhari BA, Fulda S et al:Identification of flubendazole as potential anti-neuroblastoma compound in alarge cell line screen . Scientific Reports 2015, 5(1):1-9.
  31. Ríos D, Restrepo JC: Albendazole-induced liver injury: acase report .Colombia medica (Cali, Colombia) 2013, 44 (2):118-120.
  32. Watson M: Benomyl (JMPR Evaluation 1995 Part IIToxicological and environmental) JMPR Evaluation 1995 Part IIToxicological and environmental 1995, 2.
  33. Davis A, Dixon H, Pawlowski ZS: Multicentre clinical trials of benzimidazole-carbamates in human cystic echinococcosis (phase 2).Bulletin of the World Health Organization 1989, 67 (5):503-508.
  34. Franchi C, Vico Bruno D, Teggi A: Long -Term Evaluation of Patients with Hydatidosis Treated with Benzimidazole Carbamates .Clinical Infectious Diseases 1999, 29 (2):304-309.
  35. Page SW: Antiparasitic drugs .In: Small Animal Clinical Pharmacology. edn.: Elsevier Ltd; 2008: 198-260.
  36. Cooper GM: Microtubules .2000.
  37. Dorosti Z, Yousefi M, Sharafi SM, Darani HY: Mutual action of anticancer and antiparasitic drugs: are there any shared targets? Future Oncology 2014, 10 (15):2529-2539.
  38. Narasimhan PB, Akabas L,Tariq S,Huda N, Bennuru S,Sabzevari H, Hofmeister R, Nutman TB, Tolouei Semnani R: Similarities and differences between helminth parasites and cancer cell lines in shaping human monocytes: Insights into parallel mechanisms of immune evasion .PLoS Neglected Tropical Diseases 2018, 12 (4).
  39. Juarez M, Schcolnik-Cabrera A, Due ñas-Gonzalez A: The multitargeted drug ivermectin: from an antiparasitic agent to arepositioned cancer drug .American journal of cancer research 2018, 8(2):317-331.
  40. Maude RJ, Woodrow CJ, White LJ: Artemisinin antimalarials: Preserving the "magic bullet" .In: Drug Development Research. vol. 71: Wiley-Blackwell; 2010: 12-19.
  41. Engel JA, Jones AJ, Avery VM, Sumanadasa SDM, Ng SS, Fairlie DP, Adams TS, Andrews KT: Profiling the
  42. Chen W, Mook RA, Premont RT, Wang J:Niclosamide: Beyond an antihelminthic drug .In: Cellular Signalling. vol. 41: Elsevier Inc.; 2018: 89-96.
  43. Sharma N, Thomas S, Golden EB, Hofman FM, Chen TC, Petasis NA, Sch önthal AH, Louie SG: Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent .Cancer Letters 2012, 326 (2):143-154.
  44. Guzm án EA, Johnson JD, Linley PA, Gunasekera SE, Wright AE: A novel activity from an old compound: Manzamine Areduces the metastatic potential of AsPC-1 pancreatic cancer cells and sensitizes them to TRAIL-induced apoptosis .Investigational new drugs 2011, 29 (5):777-785.
  45. Hasanpourghadi M, Karthikeyan C, Pandurangan AK, Looi CY, Trivedi P,Kobayashi K, Tanaka K, Wong WF, Mustafa MR: Targeting of tubulin polymerization and induction of mitotic blockage by Methyl 2-(5-fluoro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylate (MBIC) in human cervical cancer HeLa cell .Journal of Experimental and Clinical Cancer Research 2016, 35 (1):58-58.
  46. Di Cesare E, Verrico A, Miele A, Giubettini M, Rovella P,Coluccia A, Famiglini V,La Regina G, Cundari E, Silvestri Ret al:Mitotic cell death induction by targeting the mitotic spindle with tubulin-inhibitory indole derivative molecules .Oncotarget 2017, 8(12):19738-19759.
  47. Meissner M, Pinter A, Michailidou D, Hrgovic I, Kaprolat N, Stein M, Holtmeier W, Kaufmann R, Gille J: Microtubule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mechanisms .Journal of Investigative Dermatology 2008, 128 (8):2084-2091.
  48. Abhinand CS, Raju R, Soumya SJ, Arya PS, Sudhakaran PR: VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis .Journal of Cell Communication and Signaling 2016, 10 (4):347-354.
  49. Carbonaro M, Escuin D, O'Brate A, Thadani-Mulero M, Giannakakou P: Microtubules regulate hypoxia-inducible factor-1 αprotein trafficking and activity: Implications for taxane therapy .Journal of Biological Chemistry 2012, 287 (15):11859-11869.
  50. Sermeus A, Genin M, Maincent A, Fransolet M, Notte A, Leclere L, Riquier H, Arnould T, Michiels C: Hypoxia-Induced Modulation of Apoptosis and BCL-2 Family Proteins in Different Cancer Cell Types .PLoS ONE 2012, 7(11):e47519-e47519.
  51. Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q, Griendling KK: Reactive oxygen species in metabolic and inflammatory signaling .In: Circulation Research. vol. 122: Lippincott Williams and Wilkins; 2018: 877-902.
  52. Bhatti JS, Bhatti GK, Reddy PH: Mitochondrial dysfunction and oxidative stress in metabolic disorders — A step towards mitochondria based therapeutic strategies .In: Biochimica et Biophysica Acta -Molecular Basis of Disease. vol. 1863: Elsevier B.V.; 2017: 1066-1077.
  53. Mrkvov áZ, Uldrijan S,Pombinho A, Bart ůněkP,Slaninov áI:Benzimidazoles downregulate MDM2 and MDMX and activate p53 in MDMX overexpressing tumor cells .Molecules 2019, 24 (11).
  54. Tejada P,Sanchez-Moreno M, Monteoliva M, Gomez-Banqueri H: Inhibition of malate dehydrogenase enzymes by benzimidazole anthelmintics .Veterinary Parasitology 1987, 24 (3-4):269-274.
  55. Nguyen PTM, Baldeck JD, Olsson J, Marquis RE: Antimicrobial actions of benzimidazoles against oral streptococci .Oral Microbiology and Immunology 2005, 20 (2):93-100.
  56. Barrowman MM, Marriner SE, Bogan JA: The fumarate reductase system as asite of anthelmintic attack in Ascaris suum .Bioscience Reports 1984, 4(10):879-883.
  57. Singla P,Luxami V, Paul K: Benzimidazole-biologically attractive scaffold for protein kinase inhibitors .In: RSC Advances. vol. 4: The Royal Society of Chemistry; 2014: 12422-12440.
  58. Pereira GAN, Santos LH, Wang SC, Martins LC, Villela FS, Liao W, Dessoy MA, Dias LC, Andricopulo AD, Costa MAF
  59. Castro LSEW, Kviecinski MR, Ourique F,Parisotto EB, Grienevicius VMAS, Correia JFG, Wilhelm Filho D, Pedrosa RC: Albendazole as apromising molecule for tumor control .Redox Biology 2016, 10 :90-99.
  60. Dogra N, Kumar A, Mukhopadhyay T: Fenbendazole acts as amoderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways .Scientific Reports 2018, 8(1):1-15.
  61. Gu M, Zhang Y, Zhou X, Ma H, Yao H, JiF: Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines .Oncology Letters 2014, 8(4):1739-1744.
  62. Pinto LC, Soares BM, Pinheiro JdJV, Riggins GJ, Assump çãoPP, Burbano RMR, Montenegro RC: The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model .Toxicology in Vitro 2015, 29 (8):2038-2044.
  63. Xu D, Tian W, Jiang C,Huang Z,Zheng S:The anthelmintic agent oxfendazole inhibits cell growth in non -small cell lung cancer by suppressing c-Src activation .Molecular Medicine Reports 2019, 19 (4):2921-2926.
  64. Lin S, Yang L, Yao Y,Xu L, Xiang Y,Zhao H, Wang L, Zuo Z, Huang X, Zhao C: Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy .Journal of Experimental and Clinical Cancer Research 2019, 38 (1):293-293.
  65. Dai X, Wang L, Deivasigamni A, Looi CY, Karthikeyan C, Trivedi P, Chinnathambi A, Alharbi SA, Arfuso F, Dharmarajan A et al:A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinoma .Oncotarget 2017, 8(8):12831-12842.
  66. Chen Q, Li Y, Zhou X, Li R: Oxibendazole inhibits prostate cancer cell growth .Oncology Letters 2018, 15 (2):2218-2226.
  67. Pourgholami MH, Woon L,Almajd R, Akhter J,Bowery P,Morris DL: In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole .In: Cancer Letters. vol. 165; 2001: 43-49.
  68. Sasaki J-i, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T: The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells . Molecular cancer therapeutics 2002, 1(13):1201-1209.
  69. Popovi ćDJ, Lalo ševi ćD, Popovi ćKJ, Čapo I,Popovi ćJK, Miljkovi ćD: Effect of mebendazole on fibrosarcoma in hamsters .Tropical Journal of Pharmaceutical Research 2017, 16 (10):2445-2451.
  70. Mukhopadhyay T, Sasaki J-i, Ramesh R, Roth JA: Mebendazole Elicits aPotent Antitumor Effect on Human Cancer Cell Lines Both in Vitro and in Vivo .Clinical Cancer Research 2002, 8(9):2963-2969.
  71. Noorani L, Stenzel M, Liang R, Pourgholami MH, Morris DL: Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model .Journal of Nanobiotechnology 2015, 13 (1):25-25.
  72. Florio R, Carradori S, Veschi S, Brocco D, Di Genni T, Cirilli R, Casulli A, Cama A, De Lellis L: Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy .Pharmaceuticals (Basel) 2021, 14 (4).
  73. Abd El-Karim SS, Anwar MM, Zaki ER, Elseginy SA, Nofal ZM: Synthesis and molecular modeling of new benzimidazoles as glutathione S-transferase inhibitors and anticancer agents .Future Medicinal Chemistry 2018, 10 (2):157-181.
  74. Karaaslan C, Bakar F, Goker H: Antiproliferative activity of synthesized some new benzimidazole carboxamidines against MCF-7 breast carcinoma cells .Zeitschrift fur Naturforschung -Section CJournal of Biosciences 2018, 73 (3-4):137-145.
  75. Maji B, Kumar K, Kaulage M, Muniyappa K, Bhattacharya S: Design and synthesis of new benzimidazole-carbazole conjugates for the stabilization of human telomeric DNA, telomerase inhibition,
  76. Liu J-F, Huang Y-L, Yang W-H, Chang C-S, Tang C-H: 1-Benzyl-2-Phenylbenzimidazole (BPB), aBenzimidazole Derivative, Induces Cell Apoptosis in Human Chondrosarcoma through Intrinsic and Extrinsic Pathways . International Journal of Molecular Sciences 2012, 13 (12):16472-16488.
  77. Yeong KY, Nor Azizi MIH, Berdigaliyev N, Chen WN, Lee WL, Shirazi AN, Parang K: Sirtuin inhibition and anti-cancer activities of ethyl 2-benzimidazole-5-carboxylate derivatives . MedChemComm 2019, 10 (12):2140-2145.
  78. Paul K, Sharma A, Luxami V: Synthesis and in vitro antitumor evaluation of primary amine substituted quinazoline linked benzimidazole .Bioorganic and Medicinal Chemistry Letters 2014, 24 (2):624-629.
  79. Rashid M, Husain A, Mishra R, Karim S,Khan S,Ahmad M, Al-wabel N, Husain A, Ahmad A, Khan SA: Design and synthesis of benzimidazoles containing substituted oxadiazole, thiadiazole and triazolo-thiadiazines as a source of new anticancer agents .Arabian Journal of Chemistry 2019, 12 (8):3202-3224.
  80. Suk F-M, Liu C-L, Hsu M-H, Chuang Y-T, Wang JP, Liao Y-J: Treatment with anew benzimidazole derivative bearing apyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma .Scientific Reports 2019, 9(1):17259.
  81. Spengler G, Kincses A, Rácz B, Varga B, Watanabe G, Saijo R, Sekiya H, Tamai E, Maki J, Moln árJet al: Benzoxazole-based Zn(II) and Cu(II) Complexes Overcome Multidrug-resistance in Cancer .Anticancer Res 2018, 38 (11):6181-6187.
  82. Movahedi F, Gu W, Soares CP, Xu ZP: Encapsulating Anti-Parasite Benzimidazole Drugs into Lipid-Coated Calcium Phosphate Nanoparticles to Efficiently Induce Skin Cancer Cell Apoptosis .Frontiers in Nanotechnology 2021, 3:44-44.
  83. Parker AL, Kavallaris M, McCarroll JA: Microtubules and their role in cellular stress in cancer .Frontiers in oncology 2014, 4:153-153.
  84. Choi DG, Venkatesan J, Shim MS: Selective anticancer therapy using pro-oxidant drug-loaded chitosan –fucoidan nanoparticles .International Journal of Molecular Sciences 2019, 20 (13).
  85. Wang M, Wu Y, Xu C, Zhao R, Huang Y, Zeng X, Chen T: Design and Synthesis of 2-(5-Phenylindol -3-yl)benzimidazole Derivatives with Antiproliferative Effects towards Triple -Negative Breast Cancer Cells by Activation of ROS -Mediated Mitochondria Dysfunction .Chemistry –An Asian Journal 2019, 14 (15):2648-2655.
  86. Ullah A, Shah F,Khan I,Anwar M, Shah K, Muhammad MT, Ahmad F: Unprecedented chemosensing behavior of novel tetra-substituted benzimidazole zinc(II) phthalocynine for selective detection of Bi3 +ion: Synthesis, characterization and ROS generation .Spectrochimica Acta -Part A: Molecular and Biomolecular Spectroscopy 2018, 192 :188-193.
  87. Williamson T,Mendes TB, Joe N, Cerutti JM, Riggins GJ: Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer .Endocrine-Related Cancer 2020, 27 (3):123-136.
  88. Oh E, Kim Y-J, An H, Sung D, Cho T-M, Farrand L, Jang S, Seo JH, Kim JY: Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition .International Journal of Cancer 2018, 143 (8):1978-1993.
  89. Zhang B, Ling T, Zhaxi P,Cao Y, Qian L, Zhao D, Kang W, Zhang W, Wang L, Xu Get al:Proton pump inhibitor pantoprazole inhibits gastric cancer metastasis via suppression of telomerase reverse transcriptase gene expression .Cancer Letters 2019, 452 :23-30.
  90. Wu Y,Li G, He D, Yang F,He G, He L, Zhang H, Deng Y,Fan M, Shen Let al:Telomerase reverse transcriptase methylation predicts lymph node metastasis and prognosis in patients with gastric cancer .OncoTargets and Therapy 2016, 9:279-286.
  91. Peitzsch C, Tyutyunnykova A, Pantel K, Dubrovska A: Cancer stem cells: The root of tumor recurrence and metastases .In: Seminars in Cancer Biology. vol. 44: Academic Press; 2017: 10-24.
  92. Ren Yuan B, Staedtke V,Aprhys CM, Gallia GL, Riggins GJ: Antiparasitic mebendazole shows survival benefit in 2preclinical models of glioblastoma multiforme .In: Neuro-Oncology. 2011: 13(19):974-982.
  93. Zhang L,Bochkur Dratver M, Yazal T,Dong K, Nguyen A, Yu G, Dao A, Bochkur Dratver M, Duhachek-Muggy S,Bhat Ket al:Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer .International Journal of Radiation Oncology Biology Physics 2019, 103 (1):195-207.
  94. Khalilzadeh A, Wangoo KT, Morris DL, Pourgholami MH: Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: Involvement of apoptotic pathways .Biochemical pharmacology 2007, 74 (3):407-414.
  95. Chu SWL, Badar S,Morris DL, Pourgholami MH: Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole .Anticancer research 2009, 29 (10):3791-3796.
  96. Carpenter RD, Andrei M, Lau EY, Lightstone FC, Liu R, Lam KS, Kurth MJ: Highly potent, water soluble benzimidazole antagonist for activated α4β1 integrin . Journal of Medicinal Chemistry 2007, 50 (23):5863-5867.
  97. Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE: Kupffer cells in the liver .Compr Physiol 2013, 3(2):785-797.
  98. Blanco E, Shen H, Ferrari M: Principles of nanoparticle design for overcoming biological barriers to drug delivery .In: Nature Biotechnology. vol. 33: Nature Publishing Group; 2015: 941-951.
  99. Bilardo R, Traldi F, Vdovchenko A, Resmini M: Influence of surface chemistry and morphology of nanoparticles on protein corona formation .Wiley Interdiscip Rev Nanomed Nanobiotechnol 2022, 14 (4):e1788.
  100. He C, Hu Y, Yin L, Tang C, Yin C: Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles .Biomaterials 2010, 31 (13):3657-3666.
  101. Champion JA, Mitragotri S: Role of target geometry in phagocytosis .Proc Natl Acad Sci U S A 2006, 103 (13):4930-4934.
  102. Subhan MA, Yalamarty SSK, Filipczak N, Parveen F,Torchilin VP: Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment .JPers Med 2021, 11 (6).
  103. Matsumura Y, Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs .Cancer Res 1986, 46 (12 Pt 1):6387-6392.
  104. Zhou W, Jia Y,Liu Y,Chen Y,Zhao P: Tumor Microenvironment-Based Stimuli-Responsive Nanoparticles for Controlled Release of Drugs in Cancer Therapy .Pharmaceutics 2022, 14 (11).
  105. Movahedi F, Wu Y, Gu W, Xu ZP: Nanostructuring aWidely Used Antiworm Drug into the Lipid-Coated Calcium Phosphate Matrix for Enhanced Skin Tumor Treatment .ACS Applied Bio Materials 2020, 3(7):4230-4238.
  106. Fern ández M, Javaid F,Chudasama V: Advances in targeting the folate receptor in the treatment/imaging of cancers .Chem Sci 2018, 9(4):790-810.
  107. Kefayat A, Hosseini M, Ghahremani F,Jolfaie NA, Rafienia M: Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment .Journal of Nanobiotechnology 2022, 20 (1):169.
  108. Liang J,Li R, He Y,Ling C, Wang Q, Huang Y,Qin J,Lu W, Wang J:Anovel tumor-targeting treatment strategy uses energy restriction via co-delivery of albendazole and nanosilver . Nano Research 2018, 11 (9):4507-4523.
  109. Rathore A, Jain A, Gulbake A, Shilpi S,Khare P,Jain A, Jain SK: Mannosylated liposomes bearing Amphotericin B
  110. Graves RA, Ledet GA, Nation CA, Pramar YV, Bostanian LA, Mandal TK: Effect of squalane on mebendazole-loaded Compritol ® nanoparticles .Journal of Biomaterials Science, Polymer Edition 2015, 26 (13):868-880.
  111. Manal A, El-Melegy N, Ghoneim S, Mohamed N, El-Dien N, Rizk M: Silver Nano Particles Improve the Therapeutic Effect of Mebendazole Treatment during the Muscular Phase of Experimental Trichinellosis . In: Journal of American Science. 2019.
  112. Mart ín-de-Luc íaI, Gon çalves SF, Legan ésF, Fern ández-Pi ñas F, Rosal R, Loureiro S: Combined toxicity of graphite-diamond nanoparticles and thiabendazole to Daphnia magna .Science of the Total Environment 2019, 688 :1145-1154.
  113. Zhang XN, Zhang Q, Wen H, Wang GQ, Sun DJ: Preparation of albendazole polybutycyanocrylate nanoparticles and study on its pharmaceutical properties and tissue distribution .Yaoxue Xuebao 2003, 38 (6):462-466.
  114. Aminpour S, Rafiei A, Jelowdar A, Kouchak M: Evaluation of the Protoscolicidal Effects of Albendazole and Albendazole Loaded Solid Lipid Nanoparticles .Iranian journal of parasitology 2019, 14 (1):127-135.
  115. Farhadi M, Haniloo A, Rostamizadeh K, Faghihzadeh S: Efficiency of flubendazole-loaded mPEG-PCL nanoparticles: Apromising formulation against the protoscoleces and cysts of Echinococcus granulosus . Acta Trop 2018, 187 :190-200.
  116. Kang B-S, Choi J-S, Lee S-E, Lee J-K, Kim T-H, Jang WS, Tunsirikongkon A, Kim J-K, Park J-S: Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles .Carbohydrate Polymers 2017, 159 :39-47.
  117. Noorani L, Stenzel M, Liang R, Pourgholami MH, Morris DL: Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model .Journal of Nanobiotechnology 2015, 13 (1):25.
  118. Simbulan-Rosenthal CM, Dakshanamurthy S,Gaur A, Chen YS, Fang HB, Abdussamad M, Zhou H, Zapas J,Calvert V, Petricoin EF et al:The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma .Oncotarget 2017, 8(8):12576-12595.
  119. Coyne CP: Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole .Journal of Cancer Research and Therapeutic Oncology 2013, 2(1).
  120. Ehteda A, Galettis P, Pillai K, Morris DL: Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice .BMC cancer 2013, 13 :86-86.
  121. Florio R, Veschi S,Di Giacomo V,Pagotto S,Carradori S,Verginelli F,Cirilli R, Casulli A, Grassadonia A, Tinari Net al: The benzimidazole-based anthelmintic parbendazole: Arepurposed drug candidate that synergizes with gemcitabine in pancreatic cancer .Cancers 2019, 11 (12).
  122. Gao P, Dang CV, Watson J: Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins .Journal of the American Association for Laboratory Animal Science 2008, 47 (6):37-40.
  123. Shin HJ, Jo MJ, Jin IS, Park C-W, Kim J-S, Shin DH: Optimization and Pharmacokinetic Evaluation of Synergistic Fenbendazole and Rapamycin Co-Encapsulated in Methoxy Poly(Ethylene Glycol)-b-Poly(Caprolactone) Polymeric Micelles .International Journal of Nanomedicine 2021, Volume 16 :4873-4889.
  124. Movahedi F, Liu J, Sun B, Cao P, Sun L, Howard C, Gu W, Xu ZP: PD-L1-Targeted Co-Delivery of Two Chemotherapeutics for Efficient Suppression of Skin Cancer Growth .Pharmaceutics 2022, 14 (7).
  125. Patel K, Doudican NA, Schiff PB, Orlow SJ: Albendazole sensitizes cancer cells to ionizing radiation .Radiation oncology (London, England) 2011, 6:160-160.
  126. Can Nn, Evik UA, Sagl ıkBmN, Zkay Y, Atl ıZ, Baysal M, Zkay mD, Can zrD: Pharmacological and Toxicological
  127. Weber PBGBDW: The Effects of Triclabendazole on the Lung Fluke, Paragonimus Uterobilateralis in the Experimental Host Sigmodon Hispidus - PubMed . In: Trop Med Parasitol. 1988: 39(34):322 –324.-339(324):322 –324.
  128. Jaroonvesama N, Charoenlarp K, Cross JH: Treatment of Opisthorchis Viverrini With Mebendazole -PubMed . In: Southeast Asian JTrop Med Public Health. 1981: 595-597.
  129. Talaie H, Emami H, Yadegarinia D, Nava-Ocampo AA, Massoud J,Azmoudeh M, Mas-Coma S: Randomized trial of asingle, double and triple dose of 10 mg/kg of ahuman formulation of triclabendazole in patients with fascioliasis .Clinical and Experimental Pharmacology and Physiology 2004, 31 (11):777-782.
  130. Marti OG, Stewart TB, Hale OM: Comparative Efficacy of Fenbendazole, Dichlorvos, and Levamisole HCl against Gastrointestinal Nematodes of Pigs .The Journal of Parasitology 1978, 64 (6):1028-1028.
  131. Gasilina A, Premnauth G, Gurjar P,Biesiada J,Hegde S,Milewski D, Ma G, Kalin TV, Merino E,Meller Jet al:IODVA1, aguanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models .PLoS ONE 2020, 15 (3):e0229801-e0229801.
  132. De Witt M, Gamble A, Hanson D, Markowitz D, Powell C, Al Dimassi S,Atlas M, Boockvar J,Ruggieri R, Symons M: Repurposing mebendazole as areplacement for vincristine for the treatment of brain tumors .Molecular Medicine 2017, 23 :50-56.